MedTrace Logo

The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)

NCT01454440 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2011-10-19

No results posted yet for this study

Summary

Patients with stable coronary artery disease, undergoing PCI by means of implantation of \>33 mm of DES, will be randomized single-blinded to eptifibatide plus unfractioned heparin according to the ESPRIT protocol vs placebo plus unfractioned heparin.

Conditions

Interventions

DRUG

Eptifibatide

Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01454440 on ClinicalTrials.gov